Corvus Pharmaceuticals (CRVS) Non Operating Income (2025 - 2026)

Corvus Pharmaceuticals' (CRVS) quarterly Non Operating Income came in at $1.2 million in Q1 2026, down 95.28% year-on-year from $25.1 million in Q1 2025, and down 95.28% quarter-over-quarter from $25.1 million in Q1 2025.

Corvus Pharmaceuticals (CRVS) Non Operating Income (2025 - 2026) Analysis & Trends

Corvus Pharmaceuticals' Non Operating Income history runs 2 years deep, the most recent figure standing at $1.2 million for Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Op. Inc. (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -9.22 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 188.30 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - 5.75 Mn
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -8.59 Mn
10 Corvus Pharmaceuticals 1.23 Bn 1.23 Bn - 1.19 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 1.19 Mn
Mar 31, 2025 25.12 Mn